Pralidoxime Chloride
(Pralidoxime)Phase 1Small molecule
Pralidoxime Chloride is one of 18 small molecule programs targeting Poisoning. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
17
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Poisoning
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Nimotop
AAzurity Pharmaceuticals
Phase 3
Osmitrol
BB. Braun Medical Inc.
Phase 3
Esmeron
FFresenius Kabi Oncology Ltd.
Phase 3
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Sodium Hypochlorite
AAya Sabry Mohamed Mohamed
Approved
Atropine Sulfate
CCloudbreak Therapeutics, LLC
Phase 3
Atropen
FFresenius Kabi Oncology Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Poisoning3 trials
Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime
Completed·—·Phase 2·NCT06111352·96 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PROTOPAM CHLORIDE
NDA NDA014134
Jan 1, 1982
PROTOPAM CHLORIDE
NDA NDA014122
Dec 13, 1982
PRALIDOXIME CHLORIDE
NDA NDA018799
Apr 26, 1983
PRALIDOXIME CHLORIDE (AUTOINJECTOR)
NDA NDA018986
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pralidoxime. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- WWyeth-Lederle Vaccines